Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.41 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11548652 | 0.88 | AKR1B1 (0.53) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| SCHEMBL30359 | 0.84 | AKR1B1 (0.76) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| SCHEMBL29410826 | 0.84 | AKR1B1 (0.76) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| SCHEMBL76036 | 0.83 | AKR1B1 (0.61) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| SCHEMBL28842838 | 0.82 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| Hydrogen Sulfide SCHEMBL27426416 | 0.82 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| Hydrochloric Acid SCHEMBL9621764 | 0.82 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| Hydrochloric Acid SCHEMBL6767821 | 0.82 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| Iodide SCHEMBL31305035 | 0.82 | AKR1B1 (0.73) | AKR1B1TDP1BCAT2CXCL8KDM4E | |
| SCHEMBL3124446 | 0.81 | AKR1B1 (0.59) | AKR1B1TDP1BCAT2PTPN1CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488748-B2 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-10 | — | — | US | disclosed |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
| EP-1590325-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067510-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | AKR1B1 436/4885TDP1 4627/4885BCAT2 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.